Reducing the damage sustained by the heart during a myocardial infarction remains one of the major challenges in cardiology, ...

A heart attack is far from an isolated, acute event. The consequences of an attack can cause serious and lasting damage, ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

Heart failure (HF), a common complication of myocardial infarction (MI), occurs in 14%-36% of hospitalized patients. Patients with HF can present with a wide spectrum of clinical severity, ranging ...

The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing diuretic ...

THE recent availability of pure L-nor-epinephrine (arterenol, nor-adrenaline) has permitted evaluation of its clinical usefulness as a pressor agent. Preliminary reports 1–7 have suggested beneficial ...

The largest analysis aimed at more accurately predicting the risk of sudden cardiac death after myocardial infarction is presented in late breaking results from the PROFID consortium at ESC Congress ...